Abstract: Objective  To systematically evaluate the effect of glucagonlike peptide 1（GLP1） receptor agonist（RA) on islet cell function in overweight and obese patients  with type 2 diabetes. Methods  A computerbased search of relevant databases at home and abroad to find a randomized controlled trial (RCT) of GLP1 RA in overweight and obese patients with type 2 diabetes. Results  Finally  13 RCT were selected, indicating GLP1 RA  significantly improved the fasting blood glucose (FPG) and glycosylated hemoglobin (HbA1c) in obese patients with type 2 diabetes,  and showed significant advantages in improving body weight,  and GLP1 RA  could greatly  improve. Islet cell function in obese patients (MD=5.80,  95%CI=3.168.45,P<0.01). Conclusion  In overweight and obese patients,  GLP1 RA can significantly improve blood glucose and lose weight,  and it has  proved  the advantage of protecting islet cell function from different aspects. Such drugs provide a new choice for obese and overweight patients to reduce blood glucose.

Key words: glucagonlike peptide 1, receptor agonist, diabetes, , type 2, obesity, metaanalysis